The study aimed to explore the combined effects of Metformin, vitamin D, and calcium supplementation on insulin resistance in obese African American adolescent females, a demographic with significant health disparities. The market potential is notable given the rising prevalence of obesity and related metabolic disorders in adolescents, particularly within minority populations. However, the trial was withdrawn due to poor recruitment, indicating potential challenges in patient engagement and recruitment strategies for similar studies. This raises concerns about the feasibility of future trials targeting this demographic and the need for tailored outreach and support mechanisms. Competitive implications suggest that alternative interventions or combinations may need to be explored to address insulin resistance effectively in this population.